CLINICAL_TRIALS ClinicalTrials.gov record update

PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04459273
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:29.752749+00:00
Published At: 2026-02-05T00:00:00+00:00
Record Updated At: 2026-02-05
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Bladder Carcinoma", "Cervical Carcinoma", "Cholangiocarcinoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Hepatocellular Carcinoma", "Malignant Adrenal Gland Neoplasm", "Malignant Brain Neoplasm", "Malignant Pleural Neoplasm", "Malignant Skin Neoplasm", "Malignant Solid Neoplasm", "Malignant Testicular Neoplasm", "Malignant Thymus Neoplasm", "Neuroendocrine Neoplasm", "Thyroid Gland Carcinoma", "Urothelial Carcinoma", "Cancer of Unknown Primary Site"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-02-05"
protocolSection.identificationModule.nctId: "NCT04459273"
protocolSection.identificationModule.officialTitle: "PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.